SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Nichol MB, Knight TK, Dow T et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: Comparison of anticoagulation clinic versus usual care. Ann Pharmacother 2008;42:6270.
  • 2
    Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133 (6 Suppl):160S198S.
  • 3
    Ageno W, Johnson J, Nowacki B et al. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy. Thromb Haemost 2000;83:849852.
  • 4
    Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:16411647.
  • 5
    Poller L, Shiach CR, MacCallum PK et al. Multicentre randomised study of computerised anticoagulant dosage. European concerted action on anticoagulation. Lancet 1998;352:15051509.
  • 6
    Garcia D, Regan S, Crowther M et al. Warfarin maintenance dosing patterns in clinical practice: Implications for safer anticoagulation in the elderly population. Chest 2005;127:20492056.
  • 7
    Merli GJ, Tzanis G. Warfarin: What are the clinical implications of an out-of-range-therapeutic international normalized ratio? J Thromb Thrombolysis 2009;27:293299.
  • 8
    Siguret V, Gouin I, Debray M et al. Initiation of warfarin therapy in elderly medical inpatients: A safe accurate regimen. Am J Med 2005;118:137142.
  • 9
    Bal dit Sollier C, Cambus C, Mahé I et al. A multi-rule expert system to manage OAT in most real-life clinical situations. J Thromb Haemost 2005;3 (Supp 1):P1623.
  • 10
    Ansell J. Tthe seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126 (3 Suppl):204S233S.
  • 11
    Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692694.
  • 12
    Rosendaal FR, Cannegieter SC, van der Meer FJ et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236239.
  • 13
    van Walraven C, Jennings A, Oake N et al. Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest 2006;129:11551166.
  • 14
    Witt DM, Sadler MA, Shanahan RL et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005;127:15151522.
  • 15
    van Walraven C, Austin PC, Oake N et al. The effect of hospitalization on oral anticoagulation control: A population-based study. Thromb Res 2007;119:705714.
  • 16
    Ansell J, Hollowell J, Pengo V et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: The International Study of Anticoagulation Management (ISAM). J Thromb Thrombolysis 2007;23:8391.
  • 17
    Claes N, Buntinx F, Vijgen J et al. The Belgian Improvement Study on Oral Anticoagulation Therapy: A randomized clinical trial. Eur Heart J 2005;26:21592165.
  • 18
    Vogel T, Coriol V, Kaltenbach G et al. Prospective study of oral anticoagulation control in 110 very elderly hospitalized patients and of risk factors for poor control. Presse Med 2008;37:17231730.
  • 19
    Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 2008;25:6166.
  • 20
    Veeger NJ, Piersma-Wichers M, Tijssen JG et al. Individual time within target range in patients treated with vitamin K antagonists: Main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005;128:513519.